Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis.
Eckman
M H
MH
Department of Medicine, New England Medical Center, Boston, MA 02111, USA.
Steere
A C
AC
Kalish
R A
RA
Pauker
S G
SG
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004318:Doxycycline / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008193:Lyme Disease / Q000188:drug therapy* / Q000191:economics*; D009422:Nervous System Diseases / Q000517:prevention & control; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012306:Risk
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone; D004318:Doxycycline